Emergence of tet(A) variant and blaKPC-2 co-carrying plasmid from a ST11 hypervirulent Klebsiella pneumoniae isolate in patient's gut

Carbapenem-resistant Klebsiella pneumoniae (CRKP) are increasingly reported worldwide and CRKP infections are often associated with high morbidity and mortality. Tigecycline is among the few drugs of choice for the treatment of carbapenem-resistant bacterial infections. However, tigecycline-resistant CRKP isolates have been reported in several regions with the detection rates from 9.1%-14.5% [1,2]. Until now, the mechanisms conferring tigecycline resistance in K. pneumoniae are not well characterized and elucidated.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Letter to the Editor Source Type: research